Atlas Trials

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Clinical trial NCT02096042 · TERMINATED

Trial details

NCT number
NCT02096042
Sponsor
M.D. Anderson Cancer Center
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Leukemia
Start date
2014-04-01
Primary completion
2016-08-01
Enrollment
1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.